ICU Medical, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. ICU Medical develops, manufactures and sells medical products for infusion therapy and critical care. Results include Smiths Medical from January 7 through March 26, following its acquisition on January 6, 2022.
Financial results and key metrics
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $543.1 million | $318.0 million |
| Gross profit / margin | $168.8 million / 31.1% | $112.7 million / 35.4% |
| Operating income (loss) | $(42.2) million | $26.6 million |
| Net income (loss) | $(38.1) million | $23.7 million |
| Diluted EPS | $(1.61) | $1.09 |
| Operating cash flow | $(1.3) million | $51.3 million |
| Capital expenditures | $23.6 million | $14.0 million |
Smiths Medical contributed $214.9 million in revenue and $40.4 million in net loss for its included post-acquisition period. Revenue growth therefore substantially reflects the acquisition; the filing’s unaudited pro forma results show combined revenue of $563.7 million in Q1 2022 versus $594.1 million in Q1 2021, and combined net loss of $35.0 million versus $2.0 million.
Gross margin declined mainly because Smiths Medical had lower margins, including quality-system and product-remediation spending, supply-chain-related lower manufacturing absorption, inflation and expedited freight costs. Legacy ICU margins were generally consistent with the prior year. Operating expenses rose with the acquisition and $30.7 million of strategic transaction and integration costs; total restructuring, transaction and integration expense was $33.9 million. Interest expense increased to $13.6 million from $0.2 million, primarily reflecting acquisition financing.
Balance sheet, debt and liquidity
- At March 31, cash and cash equivalents were $329.4 million; short-term investments were $14.9 million and long-term investments $2.5 million.
- Long-term debt had a $1.684 billion principal balance, with a $1.656 billion carrying value before current classification; $13.8 million was current and $1.642 billion long-term on the balance sheet. The $500 million revolving facility was undrawn.
- Cash, cash equivalents and short-term investments fell to $344.3 million from $567.2 million at year-end, mainly due to funding the Smiths Medical acquisition. The company used $1.844 billion net cash for acquisitions and received $1.673 billion net proceeds from debt issuance.
- Management stated existing cash, expected operating cash flows and available credit facilities should provide sufficient liquidity for the next 12 months. The company was in compliance with its financial covenants at quarter-end.
- Inventory rose to $536.3 million from $290.2 million, primarily reflecting acquired inventory and increased safety stock. Operating cash flow was negative as working-capital movements, including inventory, accrued liabilities and taxes, used cash.
Material changes, outlook and risks
- Smiths Medical acquisition: Consideration included approximately $1.9 billion cash, 2.5 million ICU shares valued at $576.0 million, and contingent consideration. The preliminary allocation recorded $1.493 billion goodwill and $925 million acquired intangible assets; purchase accounting remains subject to revision.
- Existing product lines were mixed: Infusion Consumables revenue increased 11.2% to $140.5 million; Infusion Systems increased 3.2% to $87.0 million; IV Solutions declined 6.1% to $88.5 million, primarily due to lower Pfizer contract-manufacturing sales; Critical Care declined 6.9% to $12.2 million. Three newly reported Smiths Medical lines added $214.9 million combined.
- Smiths Medical’s Oakdale facility had received an FDA Warning Letter in 2021 citing medical-device reporting and quality-system issues. The acquired field-service corrective-action estimate was $54.7 million at March 31, 2022; actual costs may differ and depend on work needed to achieve regulatory clearance.
- The Smiths acquisition includes a potential $100 million cash earn-out tied to ICU share-price targets; its March 31 fair value was $53.5 million. Other contingent earn-outs also remain outstanding.
- Management highlighted integration execution, customer and employee retention, supply-chain disruptions, inflation and freight, COVID-19 uncertainty, competition, foreign exchange and rising interest rates as risks. A 1% SOFR movement was estimated to change annual term-loan interest expense by approximately $17 million before considering hedging effects. Interest-rate swaps hedge portions of the variable-rate debt.
- No specific revenue or earnings guidance is provided in the filing. Management said planned 2022 capital expenditures and expected restructuring, integration and quality-compliance spending estimates had not materially changed from the 2021 Form 10-K.
Important facts for investors to verify
- Progress and costs of integrating Smiths Medical, and whether its acquired operations improve margins and cash generation.
- Final purchase-price allocation, acquired intangible amortization and any subsequent remeasurement of the $100 million earn-out.
- FDA remediation milestones, regulatory clearance, and whether the $54.7 million field-action estimate is sufficient.
- Debt paydown, covenant headroom, variable-rate exposure and liquidity as working-capital needs evolve.
- Underlying revenue trends in legacy product lines, especially IV Solutions and Pfizer-related sales, separate from acquisition-driven growth.